Serena Williams Weight Loss Medication Endorsement

Serena Williams’s GLP-1 Partnership: A Game, Set, and Match for the Weight-Loss Drug Industry

Serena Williams’s recent disclosure of using GLP-1 medications for weight loss has ignited a conversation about the role of these drugs, even as her simultaneous partnership with a telehealth company selling them raises questions of influence and clarity.

Postpartum weight Struggles and a Search for Solutions

Williams detailed her struggles to lose weight after childbirth, acknowledging that even her rigorous training regimen – “running, walking, biking, stair climbing” – proved insufficient. “As an athlete and as someone that has done everything, I just couldn’t get my weight to where I needed to be at a healthy place, and believe me I don’t take shortcuts. I do everything but shortcuts,” she stated in an interview on NBC’s Today show. She expressed a need “to try something different” in a conversation with Elle magazine.

beyond postpartum weight loss, Williams cited family history of diabetes and concerns about knee pressure as contributing factors to her decision. the influence of friends already using GLP-1s also played a role.

Breaking the Stigma, But at What Cost?

Williams’s stated goal of destigmatizing weight-loss drugs and fostering “a more open conversation” will likely resonate with users of medications like mounjaro who face judgment. However, her position as a spokesperson for Ro, a US telehealth company selling Wegovy (semaglutide) and Zepbound (tirzepatide, known as Mounjaro internationally), complicates the narrative.

Her husband, Reddit co-founder Alexis Ohanian, is an investor in Ro and serves on its board. While both Williams and Ro have been clear about this connection, some observers remain uneasy about the potential conflict of interest.

A High-Profile Endorsement

Williams isn’t the first athlete to promote GLP-1s, but she is by far the most recognizable and influential. Her past success overcoming health challenges, combined with her resilience and character, have established her as a powerful role model.

This partnership effectively delivers a “game, set, and match” to an industry poised to benefit from expanding the user base of GLP-1s.A Ro spokesperson told Reuters, “Serena knows people may be surprised to learn that she would use a GLP-1, and that’s exactly why we think she is the perfect person to share her story.”

Unparalleled influence and Financial Power

Despite Coco Gauff’s recent rise as the highest-paid active sportswoman (according to Forbes), Williams retains significant influence and celebrity status. Her career prize money of $94.8 million is more then double that of the next highest earner (currently Venus Williams). Forbes estimates her total net worth at $350 million as of March.

Williams’s venture capital firm, Serena Ventures, focuses on investing in early-stage companies with diverse leadership. She also receives business advice from consello Group, founded by Declan Kelly, since April 2024.

The Power of Advertising and Sponsorship

The partnership with Ro is highly likely to be a commercial success, in part due to the legality of prescription drug advertising in the US. even in Canada,where restrictions exist,the prominent display of the Ozempic brand at the Canadian Open in montreal – visible behind players during matches – underscored the growing visibility of these drugs.

This visibility is particularly noteworthy given that the World Anti-Doping Agency (wada) has added GLP-1s to its monitored substances list and plans to rule on their permissibility for athletes in 2026.

A Marketing Shortcut

While Williams will likely face criticism for her endorsement, there appears to be little resistance to the pharmaceutical companies profiting from these products, such as Denmark’s Novo Nordisk (Ozempic and Wegovy) and Eli Lilly (Mounjaro). The industry is effectively leveraging the glamour of sport and the legacy of its stars to normalize GLP-1 use. The “shortcut,” ultimately, is a marketing one, and it’s being readily exploited.